ArticleCurrent treatment options in neurology2013
Treatment of paraneoplastic cerebellar degeneration.
Article in Current treatment options in neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Neuroimmunology of Oral Cancer: Tumor Progression, Systemic Inflammation, and Neural Circuit Dysfunction from the Cerebellum to the Frontal Cortex.Molecular biology reports · 2026Review
- Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- A case of Anti-Hu and Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with stage IV adenocarcinoma of Müllerian origin.Gynecologic oncology reports · 2025Article
- Plasmapheresis and IVIG for Treatment of Non-Tumor Anti-Tr/DNER Antibody-Associated Ataxia: A Case Report.Cerebellum (London, England) · 2024Article
- Ovarian mass Presenting as Paraneoplastic cerebellar degeneration with peripheral neuropathy and anti-Yo antibody.BMJ case reports · 2024Article
- Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab.Frontiers in immunology · 2024Article
- Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series.Cerebellum (London, England) · 2023Article
- Paraneoplastic Ataxia: Antibodies at the Forefront Have Become Routine Biomarkers.Cerebellum (London, England) · 2023Article
- Treatable Ataxias: How to Find the Needle in the Haystack?Journal of movement disorders · 2022Article
- Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.European journal of neurology · 2022Article
- Therapeutic Plasma Exchange: For Cancer Patients.Cancer management and research · 2022Review
- Neurological Autoimmunity Associated With Homer-3 Antibody: A Case Series From China.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Acute-onset paraneoplastic cerebellar degeneration secondary to neuroendocrine carcinoma with atypical prognosis: a case report.The Journal of international medical research · 2021Article
- Revisiting the Clinical Phenomenology of "Cerebellar Tremor": Beyond the Intention Tremor.Cerebellum (London, England) · 2019Review
- Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.Neuropathology and applied neurobiology · 2019Article
- Acquired ataxias: the clinical spectrum, diagnosis and management.Journal of neurology · 2015Review
- Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease.International journal of hematology · 2015Article
- Guidelines for treatment of immune-mediated cerebellar ataxias.Cerebellum & ataxias · 2015Review
- Inpatient rehabilitation performance of patients with paraneoplastic cerebellar degeneration.Archives of physical medicine and rehabilitation · 2014Article
- Paraneoplastic cerebellar degeneration associated with noncutaneous Merkel cell carcinoma.Neurology(R) neuroimmunology & neuroinflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementParaneoplastic cerebellar degeneration is an uncommon autoimmune disorder characterized clinically by progressive, ultimately incapacitating ataxia and pathologically by destruction of cerebellar Purkinje cells, with variable loss of other cell populations. The disorder is most commonly associated with gynecological and breast carcinomas, small cell carcinoma of the lung, and Hodgkin's disease and in most cases comes on prior to identification of the underlying neoplasm. The hallmark of paraneoplastic cerebellar degeneration is the presence of an immune response reactive with intracellular proteins of Purkinje or other neurons or, less commonly, against neuronal surface antigens. Evidence-based treatment strategies for paraneoplastic cerebellar degeneration do not exist; and approaches to therapy are thus speculative. Diagnosis and treatment of the underlying neoplasm is critical, and characterization of the antibody response involved may assist in tumor diagnosis. Most investigators have initiated treatment with corticosteroids, plasma exchange, or intravenous immunoglobulin G. Cyclophosphamide, tacrolimus, rituximab, or possibly mycophenolate mofetil may warrant consideration in patients who fail to stabilize or improve on less aggressive therapies. Plasma exchange has been of questionable benefit when used alone but should be considered at initiation of treatment to achieve rapid lowering of circulating paraneoplastic autoantibodies. Because the course of illness is one of relentless neuronal destruction, time is of the essence in initiating treatment. Likelihood of clinical improvement in patients with longstanding symptoms and extensive neuronal loss is poor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.